Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
RESEARCH TOOLSreports
Telix Pharmaceuticals Ltd. (TLPPF) Stock Price & Analysis
42 Followers
TLPPF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.48 - $9.11
Previous Close$8.45
Volume3.00
Average Volume (3M)6.27K
Market Cap
$2.72B
Enterprise Value$2.65B
Total Cash (Recent Filing)AU$116.33M
Total Debt (Recent Filing)AU$10.45M
Price to Earnings (P/E)949.4
Beta1.20
Next Earnings
Aug 22, 2024EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding323,989,947
10 Day Avg. Volume5,748
30 Day Avg. Volume6,268
Standard Deviation0.21
R-Squared0.37
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.32Price Target Upside10.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Telix Pharmaceuticals Ltd. News
PremiumCompany Announcements
Telix Pharmaceuticals Shares to Exit Escrow
PremiumCompany Announcements
Telix Pharmaceuticals Announces Upcoming AGM
PremiumCompany Announcements
Telix Pharmaceuticals Projects Strong Growth
PremiumCompany Announcements
Telix Pharmaceuticals Advances Brain Cancer Imaging
PremiumCompany Announcements
Telix Pharmaceuticals Seeks New ASX Quotation
PremiumCompany Announcements
Telix Pharmaceuticals Expands Market QuotationOptions Prices
Currently, No data available
---
Ownership Overview
16.44% Insiders
2.37% Mutual Funds
2.89% Other Institutional Investors
78.30% Public Companies and
Individual Investors
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $4.48 and its highest was $9.11 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Currently, no data Available
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 22, 2024 which is in 120 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 22, 2024. The company reported $0.033 earnings per share for the quarter, the consensus estimate of $0.033 by $0.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is $0.02.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 323,989,960 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $0.033 in its last earnings report, expectations of $0.033. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
---
Telix Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.32 (10.30% Upside)
$9.32 (10.30% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 97%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.84%
12-Months-Change
Fundamentals
Return on Equity
3.94%
Trailing 12-Months
Asset Growth
55.31%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
---
TLPPF Earnings Call
Q4 2024
0:00 / 0:00
---
TLPPF Stock 12 Months Forecast
Average Price Target
$9.32
▲(10.30% Upside)
Technical Analysis
Best Analysts Covering TLPPF
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+62.59%
reiterated a buy rating 8 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +62.59% per trade.
---